This file is part of IDEAS, which uses RePEc data


[ Papers | Articles | Software | Books | Chapters | Authors | Institutions | JEL Classification | NEP reports | Search | New papers by email | Author registration | Rankings | Volunteers | FAQ | Blog | Help! ]

Technological Discontinuities and the Comparative Strategic Value of New Capabilites: Evidence from the Comparison of Small- and Large-Molecule Targeted Anti-Cancer Drug Discovery

Author info | Abstract | Publisher info | Download info | Related research | Statistics
Author Info
M. Lourdes Sosa
Abstract

Traditional creative destruction theories distinguish disruptions as competence-destroying or competence-enhancing to incumbents’ capabilities, with the former case resulting in incumbents’ loss of competitive advantage in in-house R&D performance (even if complementary assets aid in retaining final market share). In this paper, I propose that attention to the extent of competence destruction is necessary but not sufficient for analyses of competitive advantage in R&D through a technological discontinuity. A full analysis requires the comparison of the value added and ease of access (i.e., strategic value) of all capabilities, old and new. In other words, an analysis of competition during a transition requires assessment not only of how many of the old capabilities were lost but also what it takes to acquire the new ones. I find evidence for this proposition in qualitative and quantitative data from the transition of anti-cancer drug discovery from standard chemotherapy to targeted therapies. Among targeted therapies, I compare two variants, small- vs. large-molecule drugs, which though equally competence-destroying to chemotherapy-based drug discovery, differ in that large-molecule drugs require one more new capability: expertise in biopharmaceutical technology. By tracing the origin and evolution of biopharmaceutical technology, as well as its comparative value added, I can show a contrast in results: incumbents led in small-molecule targeted drug discovery; but they fell behind biopharmaceutical technology pioneers in large-molecule targeted drug discovery, where one of the new capabilities (i.e., expertise in biopharmaceutical technology) had higher value added and was more difficult to acquire than other new capabilities.

Download Info
To download:

If you experience problems downloading a file, check if you have the proper application to view it first. Information about this may be contained in the File-Format links below. In case of further problems read the IDEAS help page. Note that these files are not on the IDEAS site. Please be patient as the files may be large.

File URL: http://www3.druid.dk/wp/20080013.pdf
File Format: application/pdf
File Function:
Download Restriction: no

Publisher Info
Paper provided by DRUID, Copenhagen Business School, Department of Industrial Economics and Strategy/Aalborg University, Department of Business Studies in its series DRUID Working Papers with number 08-13.

Download reference. The following formats are available: HTML (with abstract), plain text (with abstract), BibTeX, RIS (EndNote, RefMan, ProCite), ReDIF
Length:
Date of creation: 2008
Date of revision:
Handle: RePEc:aal:abbswp:08-13

Contact details of provider:
Web page: http://www.druid.dk/

For technical questions regarding this item, or to correct its listing, contact: (Keld Laursen).

Related research
Keywords: R&D capabilities; incumbents; technological disruption; competence enhancing;

Statistics
Access and download statistics

Did you know? IDEAS also indexes software components.

This page was last updated on 2009-12-16.


This information is provided to you by IDEAS at the Department of Economics, College of Liberal Arts and Sciences, University of Connecticut using RePEc data on a server sponsored by the Society for Economic Dynamics.